Skip to Main Content

Advertisement intended for health care professionals

American Society of Hematology Logo Open Menu
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 126, Issue 7
August 13 2015
Blood Cover Image for Volume 126, Issue 7

Table of Contents

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY
The expanding spectrum of EBV+ lymphomas
Jonathan Said
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
INSIDE BLOOD COMMENTARY
C3dg-CR3 interaction in erythrophagocytosis
Lubka T. Roumenina
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
INSIDE BLOOD COMMENTARY
Game, set, match for factor VIII mismatch?
Connie H. Miller
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
INSIDE BLOOD COMMENTARY
COMP: an endogenous thrombin inhibitor
Pat Metharom,Michael C. Berndt
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

HOW I TREAT

How I treat T-cell acute lymphoblastic leukemia in adults
Mark R. Litzow,Adolfo A. Ferrando
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

CLINICAL TRIALS AND OBSERVATIONS

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
Clinical Trials & Observations
Samantha M. Jaglowski,Jeffrey A. Jones,Veena Nagar,Joseph M. Flynn,Leslie A. Andritsos,Kami J. Maddocks,Jennifer A. Woyach,Kristie A. Blum,Michael R. Grever,Kelly Smucker,Amy S. Ruppert,Nyla A. Heerema,Gerard Lozanski,Mona Stefanos,Brian Munneke,Jamie-Sue West,Jutta K. Neuenburg,Danelle F. James,Nathan Hall,Amy J. Johnson,John C. Byrd
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data
Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)
Clinical Trials & Observations
Nina D. Wagner-Johnston,Brian K. Link,Michelle Byrtek,Keith L. Dawson,John Hainsworth,Christopher R. Flowers,Jonathan W. Friedberg,Nancy L. Bartlett
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality
Clinical Trials & Observations Brief Report
Joaquín Martínez-López,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Bruno Paiva,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Lucía López-Anglada,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,María-Victoria Mateos,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Teresa Cedena,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,María-Belén Vidríales,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,María Auxiliadora Sáez-Gómez,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Teresa Contreras,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Albert Oriol,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Inmaculada Rapado,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Ana-Isabel Teruel,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Lourdes Cordón,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,María Jesús Blanchard,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Enrique Bengoechea,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Luis Palomera,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Felipe de Arriba,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Cecilia Cueto-Felgueroso,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Alberto Orfao,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Joan Bladé,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Jesús F. San Miguel,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group,Juan José Lahuerta,on behalf of the Grupo Español de Mieloma Múltiple/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Group
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

LYMPHOID NEOPLASIA

EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment
Clinical Trials & Observations
Alina Nicolae,Stefania Pittaluga,Shahed Abdullah,Seth M. Steinberg,Thu Anh Pham,Theresa Davies-Hill,Liqiang Xi,Mark Raffeld,Elaine S. Jaffe
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data

PLATELETS AND THROMBOPOIESIS

Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP
Andrew L. Frelinger, III,Rachael F. Grace,Anja J. Gerrits,Michelle A. Berny-Lang,Travis Brown,Sabrina L. Carmichael,Ellis J. Neufeld,Alan D. Michelson
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

RAP-011 improves erythropoiesis in zebrafish model of Diamond-Blackfan anemia through antagonizing lefty1
Jason Ear,Haigen Huang,Tianna Wilson,Zahra Tehrani,Anne Lindgren,Victoria Sung,Abderrahmane Laadem,Thomas O. Daniel,Rajesh Chopra,Shuo Lin
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data
Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria
Brief Report
Zhuoer Lin,Christoph Q. Schmidt,Sophia Koutsogiannaki,Patrizia Ricci,Antonio M. Risitano,John D. Lambris,Daniel Ricklin
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data

THROMBOSIS AND HEMOSTASIS

Factor VIII gene variants and inhibitor risk in African American hemophilia A patients
Clinical Trials & Observations
Devi Gunasekera,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,Ruth A. Ettinger,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,Shelley Nakaya Fletcher,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,Eddie A. James,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,Maochang Liu,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,John C. Barrett,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,Janice Withycombe,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,Dana C. Matthews,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,Melinda S. Epstein,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,Richard J. Hughes,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators,Kathleen P. Pratt,on behalf of the Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data
Cartilage oligomeric matrix protein is a natural inhibitor of thrombin
Ying Liang,Yi Fu,Ruomei Qi,Meili Wang,Nan Yang,Li He,Fang Yu,Jian Zhang,Cai-Hong Yun,Xian Wang,Junling Liu,Wei Kong
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data
Activated protein C β-glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury
Brief Report
Eimear M. Gleeson,María G. Dichiara,Agustina Salicio,Louise M. Quinn,Clive Drakeford,Shane E. Russell,Patrick T. Walsh,Josune Orbe,José Hermida,Owen P. Smith,James S. O’Donnell,Ramón Montes,Roger J. S. Preston
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data

BLOOD WORK

A window into cutaneous adult T-cell leukemia/lymphoma
Drew Pratt,Elaine S. Jaffe
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

CORRESPONDENCE

Guidelines for determination of the number of prior lines of therapy in multiple myeloma
S. Vincent Rajkumar,Paul Richardson,Jesus F. San Miguel
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
All Issues

Advertisement intended for health care professionals

STK10 regulates platelet function in arterial thrombosis and thromboinflammation
High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition
The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3
A 3.3-Å cryo-EM structure of an engineered high-affinity human prothrombinase complex

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2025 by American Society of Hematology
 
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals